Carolyn Ianni, MD
Internal Medicine · Wilmington, DENPI 1427156769
Payments from drug & device makers
Across 159 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$582
- Johnson & Johnson$356
- Esperion Therapeutics, Inc.$263
- GSK$250
- Merck$214
- Astellas Pharma US Inc$207
- plus $923 from 14 others
What the payments were for
- Food & beverage$2,77499%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $582 |
| Johnson & Johnson | 22 | $356 |
| Esperion Therapeutics, Inc. | 13 | $263 |
| GSK | 13 | $250 |
| Merck | 15 | $214 |
| Astellas Pharma US Inc | 13 | $207 |
| Boehringer Ingelheim | 15 | $206 |
| Amarin Pharma, Inc. | 9 | $152 |
| Eisai Inc. | 2 | $111 |
| AbbVie(2 entities) | 6 | $88 |
| Kowa Pharmaceuticals America, Inc. | 6 | $85 |
| Lilly USA, LLC | 4 | $74 |
| Genentech USA, Inc. | 3 | $58 |
| Novo Nordisk | 2 | $34 |
| Bausch Health US, LLC | 2 | $33 |
| Seqirus USA Inc | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,795 in reported general payments places this provider in the 85th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 271 | $8,266 |
| Donepezil Hcl | 206 | $2,344 |
| Mirtazapine | 55 | $2,085 |
| Escitalopram Oxalate | 85 | $1,323 |
| RivastigmineRivastigmine Tartrate | 19 | $897 |
| Sertraline Hcl | 90 | $813 |
| Trazodone Hcl | 27 | $244 |
| Bupropion Hcl SrBupropion Hcl | 12 | $232 |
| Buspirone Hcl | 17 | $128 |
| Risperidone | 12 | $78 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Wilmington
- Jose CastroWilmington$27K
- Marcia Gina CastroWilmington$24K
- Robert KopeckiWilmington$15K
- Franklin AmpaduWilmington$15K
- Andrew MyersWilmington$15K
- Armand DesanctisWilmington$11K
- Carol Alvarado-BarrantesWilmington$10K
- Stuart FelzerWilmington$6K
- Terry HortonWilmington$5K
- Jerry GluckmanWilmington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.